TEVIMBRA
GrowthmAbtislelizumab-jsgr
BLASOLUTIONINJECTION
Approved
Mar 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
3/8 — Basic
TEVIMBRA (tislelizumab-jsgr) is programmed death receptor-1-directed antibody interactions [moa]. Approved for programmed death receptor-1 blocking antibody [epc]. First approved in 2024.
Drug data last refreshed 21h ago · AI intelligence enriched 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TEVIMBRA (tislelizumab-jsgr) is a monoclonal antibody that blocks the Programmed Death Receptor-1 (PD-1) pathway to enhance anti-tumor immune responses. It is indicated as a PD-1 blocking antibody for cancer immunotherapy. The drug works by releasing immune checkpoint inhibition, allowing T cells to recognize and attack cancer cells.
Growth
Early-stage product with significant growth potential but faces intense competitive pressure from established checkpoint inhibitors; expect expanding commercial infrastructure and team headcount.
Mechanism of Action
Programmed Death Receptor-1-directed Antibody Interactions
Pharmacologic Class:
Programmed Death Receptor-1 Blocking Antibody
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Roles linked to TEVIMBRA are concentrated in Commercial and Director-level positions, reflecting the product's early growth stage and need for launch execution. Job opportunities are currently limited (2 linked roles) but may expand as the product scales market penetration.
Director
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.